This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk11: Good afternoon, and welcome to the GenX Bio third quarter 2020 earnings conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session, and instructions will be given at that time. As a reminder, this conference call is being recorded. I would now like to turn the call over to Mr. Patrick Christmas, Chief Legal Officer for Regenexx Bio. You may begin.
spk01: Good afternoon, and thank you for joining us today. With us today are Ken Mills, Regenexx Bio's President and Chief Executive Officer, Dr. Steve Ficola, our Chief Medical Officer, and Vip Vasista, our Chief Financial Officer. Earlier this afternoon, Regenexx Bio released financial and operating results for the third quarter ended September 30th, 2020. The press release reporting our financial results is available on our website at www.regenexxbio.com. Today's conference call will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted and can be identified by words such as expect, plan, will, may, anticipate, believe, should, intend, and other words of similar meaning. Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties. These risks are described in the Risk Factors and the Management, Discussion, and Analysis sections of Regenexx Bio's annual report on Form 10-K for the full year ended December 31, 2019, and comparable Risk Factors sections of Regenexx Bio's quarterly reports on Form 10-Q, which are on file with the Securities and Exchange Commission and available on the SEC's website. Any information we provide on this conference call is provided only as of the date of this call, November 4th, 2020, and we undertake no obligation to update any forward-looking statements we may make on this call on account of new information, future events, or otherwise. Please be advised that today's call is being recorded and webcast. In addition, any unaudited or pro forma financial information that may be provided is preliminary and does not purport to project financial positions or operating results of the company. Actual results may differ materially. I would now like to turn the call over to Ken Mills. Ken?
spk07: Thank you, Patrick. Good afternoon, everyone. Thanks for joining us. I hope everyone is staying healthy. On today's conference call, we will provide a recap of our recent progress advancing and expanding our nav technology platform, as well as expected future milestones. Steve will provide an update on our clinical programs, and Vit will provide an update on financial results from the third quarter 2020. We'll then open up the call for questions. I'm proud to say that during this quarter, we've hit several milestones in development of our internal clinical pipeline, as two important Phase II studies evaluating RGX314 when delivered in the suprachoroidal space are now underway for the treatment of wet AMD and diabetic retinopathy. And we've expanded our MPS II program to include additional patients in the ongoing Phase I-II study of RGX121. In addition, our partners at Novartis have recently achieved significant milestone in the gene therapy space with over $1 billion in cumulative net sales of Zolgensma, a transformative one-time gene therapy for the treatment of pediatric patients with spinal muscular atrophy, and the first approved gene therapy based on Regenexx BiosNav technology platform. We're grateful to have contributed to a therapy that's impacted the lives of over 700 children with SMA and their families around the world. As always, we remain focused on the health and safety of our employees, partners, and patients during this challenging COVID-19 pandemic. We continue to actively monitor the impact that pandemic will have on our plans for preclinical and clinical development timelines, and we're focused on our general operations for the remainder of 2020 and into 2021. With that, I'd like to turn the call over to Steve for a more detailed clinical and regulatory update.
spk05: Thanks, Ken. We've been focused on development plans for the RGX314 program with several studies underway in wet AMD and diabetic retinopathy and the start of the pivotal program to come. We believe that RGX314 has the potential to profoundly impact all aspects of clinical management for patients with wet AMD and DR and could be a one-time gene therapy treatment option for a broad range of patients. Our plans for the pivotal study for the subretinal delivery of RJX314 for the treatment of wet AMD, including dose selection, number of patients, and other factors, are based on the learnings from the first in human ongoing Phase I-II study, including results from patients in cohorts 3, 4, and 5. As previously shared, these patients have demonstrated stable to improved visual acuity and retinal thickness, as well as a meaningful reduction in anti-VEGF injection burden. We also have data from cohort three out to two years, which gives us confidence in the long-term durability of the gene therapy. We now expect to initiate our pivotal program for the subretinal delivery of RGX314 for the treatment of wet AMD in the first quarter of 2021, and look forward to providing more details for this study in the coming months. In September, we announced the dosing of the first patient in the Phase II AVA trial, evaluating the supracoroidal delivery of RGX314 using the SCS microinjector for the treatment of wet AMD. The initiation of this trial was an important milestone for our company, as well as the field, as the first clinical trial to evaluate the delivery of any gene therapy to the supracoroidal space. We are excited about the potential of the targeted in-office supracoroidal approach, which may provide additional RGX314 delivery options for patients beyond subretinal delivery. Importantly, patients in this trial will not receive prophylactic immune suppressive corticosteroid therapy before or after administration of RGX314. To date, RGX314 has been well tolerated including no evidence of inflammation. We remain on track to complete enrollment of the first cohort by the end of 2020 and report initial safety data from the first cohort in early 2021. Our phase two trial altitude to evaluate supracoroidal delivery of RGX314 in patients with diabetic retinopathy is active, and we expect to begin enrolling patients by the end of 2020. DR is the leading cause of blindness in working age adults and affects approximately 8 million Americans. As the disease progresses from non-proliferative disease, a stage in which patients are often asymptomatic, to more severe disease, patients are at increased risk of developing vision-threatening complications. Most patients with non-proliferative DR often go untreated as the current standard of care is watchful waiting until vision becomes threatened. There are treatment options for patients with DR, including chronic repeated anti-VEGF injections, retinal laser treatment, and surgery. However, receiving frequent anti-VEGF intraocular injections makes the treatment a less desirable option versus watchful waiting for many asymptomatic DR patients. Unfortunately, without treatment, a large proportion of these patients will eventually develop vision-threatening complications, including diabetic macular edema and neovascularization that can lead to blindness. We believe that one-time treatment with RGX314 has the potential to provide sustainable, long-term anti-VEGF delivery, reducing severity of DR, and preventing vision-threatening complications. The altitude trial is expected to enroll 40 patients with DR across two dose cohorts. Patients will be randomized to receive RGX314 versus observational control at a three to one ratio. The primary endpoint of the study is change in diabetic retinopathy severity based on the ETDRS DRSS scale at 48 weeks, a scale well known to regulators and was actually used for approval of ILEA and Lucentis for the treatment of DR indication. Other endpoints include safety and development of diabetic retinopathy-related complications. We expect to begin dosing patients across 15 leading U.S. retina centers by the end of 2020 and plan to report interim data from this trial in 2021. Turning to our rare disease portfolio, In September, we announced the expansion of the RGX-121 program for the treatment of MPS II, including an amendment to our ongoing Phase I-II study to allow for additional patients in an expanded Cohort II. We are excited to announce that we have already dosed two more children in this cohort, and we anticipate further updates from this trial by the end of 2020. In addition, we plan to initiate a second Phase I-II multicenter open-label trial to evaluate RGX121 in older pediatric patients with severe MPS II. We plan to enroll up to six patients and administer RGX121 directly to the cerebrospinal fluid through intracisternal or intracerebroventricular injections. We also announced our plans to initiate a new observational trial designed to provide detailed characterization of neurocognitive development and key biomarkers in patients with severe MPS II. In severe forms of MPS II, early developmental milestones in a child may be met, but delays become apparent by 18 to 24 months, with neurologic deficits and cognitive impairment becoming apparent by the age of six years. This trial is intended to prospectively document the changes in neurodevelopmental parameters of cognitive, behavioral, and adaptive function over time, in addition to biomarker activity in the CSF serum and urine. We believe this study will provide critical data about the neurocognitive development of young pediatric patients with MPS II. and we look forward to sharing the data from this observational study with the patient community. We, of course, have a number of additional programs headed toward the clinic, and I look forward to 2021 being a key year for development, advancement of these gene therapy candidates, particularly within our rare disease pipeline. Notably, our programs for CLN2 disease, RGX181, which is designed to address the CNS manifestations, and RGX381, which is designed to address the ophthalmic manifestations of the disease, are on track for IND filing in the coming months. We look forward to initiating clinical trials for both these programs. With that, I turn the call back over to Ken. Ken?
spk07: Thanks, Steve. obviously very encouraged by the progress and the focus on the internal pipeline and the work by the entire team. And congrats again, Steve, on the acquisition of the new puppy. So we have a couple of things to highlight in addition to the internal program work this quarter. And as we know, Regenexx has an extensive footprint in the gene therapy space. Our nav vectors, the basis of work not only internally but also many partnered product candidates, and including one marketed product, Novartis' Zolgensma, as well as several others that are in late-stage clinical development. Our team recently collaborated with Kerma Partners, a leading European venture capital firm, to form CoreLeave Therapeutics, a new company focused on severe neurological conditions. And under the collaboration and license agreement with the newly formed CoreLeave, we have received equity as well as are eligible to receive milestone payments and royalties, in return for their use of the NAV-AEV9 vector for the treatment of refractory temporal lobe epilepsy. In addition, Olivier Danos, our chief science officer, has joined CoreLeave's board of directors and will work closely with the team on the development of the TLE program. So we're encouraged by this new development in our pipeline. And also, I wanted to highlight that, as I mentioned earlier, great progress this quarter and throughout the year so far on Zolgensma. As announced last week in our press release, Regenexx Bio has received a milestone payment of $80 million from Novartis based on the achievement of over $1 billion in cumulative net sales of Zolgensma. We're strongly encouraged by the therapy's strong global momentum and its potential to help many more patients and families. So with that, I'll turn the call over to Vit, and he can review the financials.
spk06: Thank you, Ken. Regenexx Bio ended the quarter on September 30, 2020. with cash, cash equivalents, and marketable securities totaling $289.8 million compared to $400 million as of December 31, 2019. The decrease was primarily attributable to net cash used in operating activities of $93.5 million and cash used to purchase property and equipment of $14 million. Cash reported as of September 30, 2020, excludes the recently announced $80 million milestone payment received from Novartis in October 2020, which was recorded as accounts receivable at the end of the third quarter. Revenues were $98.9 million for the quarter ended September 30, 2020, compared to $14.7 million for the third quarter of 2019. The increase was primarily attributable to a $9.6 million increase in Zulgensma royalty revenue over Q3 2019, and the one-time $80 million milestone fee recognized as revenue in the third quarter of 2020 upon the achievement of $1 billion in cumulative net sales of Zulgensma since launch. Sales of Zulgensma for the third quarter of 2020 increased by 82 percent as compared to Q3 2019. Research and development expenses were $44 million for the quarter ended September 30, 2020, compared to $35.7 million for the third quarter of 2019. The increase was primarily attributable to personal related costs as a result of increased headcount, expenses associated with conducting clinical trials for our lead product candidates, and externally sourced services for preclinical, regulatory, and manufacturing-related activities. G&A expenses were $15.9 million for the quarter ended September 30, 2020, compared to $12.4 million for the third quarter of 2019. The increase was primarily attributable to personal-related costs as a result of increased headcount and professional fees for advisory and other services. Net income was $8.8 million, or 24 cents basic and 23 cents diluted net loss per share for the three months ended September 30th, 2020, compared to a net loss of $34.6 million, or 94 cents basic and diluted net loss per share for the three months ended September 30th, 2019. As of September 30th, 2020, we had approximately 37.4 million common shares outstanding. Based on its current operating plan, Regenexx Bio expects its balance in cash equivalents and marketable securities as of September 30, 2020, in addition to the $80 million received from Novartis in October 2020, to fund its operations, including the completion of its internal manufacturing capabilities and clinical advancement of its product candidates until mid-2022. With that, I will turn the call back to Ken to provide final thoughts on yesterday's results.
spk07: Thanks, Mitt. A really good summary of the financial condition of the company and on top of Steve's updates about the program work as well as the encouraging developments with our partners, again, it continues to be a good time for Regenexx to be advancing value for patients and stakeholders. And I also wanted to highlight that the construction of our new GMP facility here in Rockville continues, a facility that allows us to manufacture at 2,000-liter scale using a fully optimized HEK293 suspension cell culture system. This is a platform that is widely utilized. and is also well understood by the regulatory agencies. So we continue to make substantial improvements in our efforts to ensure consistency of products across large volumes and across multiple programs. And in all, this has been a multi-year effort led by a great team of people that have both commercial-level expertise in biologics as well as gene therapy and a global supply chain experience that emphasizes high-quality well-characterized scalability to match the clinical and emerging commercial demands of Regenexx Bio. So we're excited about that progress and look forward to the site coming online. And in general, we look forward to making more strides towards our mission to improve lives through the curative potential of single administration gene therapies, and we remain dedicated to this mission. I want to definitely take time to express the sincere appreciation that myself and the leadership team have to our talented and dedicated employees who are driving business forward despite the challenging backdrop of the COVID-19 epidemic. With that, operator, we will turn the call over to questions.
spk11: Thank you. Ladies and gentlemen, if you have a question at this time, please press star then 1 on your telephone. If your question has been answered or you wish to remove yourself from the queue, please press the pound key. To prevent any background noise, we ask that you please place your line on mute once your question has been stated. Our first question comes from the line of Gina Wang with Barclays. Your line is open. Please go ahead.
spk09: Thank you for taking my questions. So I have two questions. The first set of questions are regarding the supercorridor microinjector program aviate trial in wet AMD. So you mentioned that you already dosed the patient. Just wondering how many patients have already been dosed? And is that right, that all the patients you've dosed so far, you haven't seen any inflammation in this patient? And then related question is regarding the safety data in the first quarter next year. Beyond the safety, I assume will be three patients from cohort one. Will you also show biomarker data and the initial efficacy data? including rescue injection and visual acuity and the OTC. And the second question is regarding the NPS2. Just wondering if you can give a little bit more color regarding the year end 20 update and what type of data and in terms of also patient numbers and type of data that we will see.
spk07: Hey, Gina. Thanks for the question or questions. Steve, maybe I'll ask you to provide an update on AV8 and just what we've seen so far and what we're thinking about for early 2021. Sure.
spk05: Hi, Gina. Thanks for the questions. Yeah, so AV8, as we disclosed today and as you mentioned, it is true that we've not seen any evidence of inflammation so far. It is still early in the trial in terms of number of patients treated. You also asked that question. We only did just announce the dosing of the first patient in early September, so not that long ago, and as is typical for an initial study with, albeit not a first in human study for RGX314. This study is a first in human for delivery to the supracoroidal space. That was actually a sentinel subject where we initially dosed and follow for a couple weeks in general to follow for overall safety and then proceed with dosing of the rest of the cohort. And we, of course, were able to do that as we've announced that we've seen no no inflammation in any of the patients that we've dosed to date. We have a total of 20 patients that we want to dose in cohort one, 15 of which will receive RGX314. We've dosed multiple patients, but we're still early in the game as far as activating all the sites. and really ramping up recruitment. And that's one of the key reasons that we're not in a position to give, for example, a more fulsome update and why, as you mentioned, we'll be giving our true initial safety update early next year. But certainly, we're encouraged by the fact that in spite of having no immune suppression at all in terms of, for example, no topical steroids before or after RGX314. To date, we're not seeing inflammation, and that's what we were able to achieve preclinically, but this being not a subretinal space, this being the first study ever looking at gene therapy in the suprachoroidal space, this is really a significant milestone in terms of assessing safety and tolerability, and importantly, whether we can achieve with AAV8 delivery, specifically with RGX314, the ability to deliver without immune suppression therapy and without inflammation. So the second part of your question in terms of what we can expect to provide in that initial safety update early in 2021, I guess fairly to manage expectations, we'll be a few more months on and we'll have a full cohort of patients that we're guiding since we still plan to complete recruitment of the 20 patients in that first cohort. And in that first update, as part of the overall assessment, certainly we continue to look at safety and tolerability first, as always, but also be able to provide some of the typical biomarker or pharmacodynamic activity measures that we've traditionally provided for our subretinal program. Though, again, we caution it's still pretty early in terms of number of months that patients have been treated, and I think we've been consistent all along for several years now in how we've talked about pharmacodynamic measures and the importance of looking at durability of treatment effect where you really want to be able to look at, for example, six months of data. So, before you really have a sense there. So, nevertheless, we still in that initial safety update would be including some of those assessments, even just from a safety perspective.
spk07: Yeah, and just a quick thanks to you for the complete answer there. And on MPS II, Gina, just quickly, you know, we do have plans for an update before the end of this year, and very pleased to have announced today two additional patients enrolled at the 6.5E10 dose level under this expanded protocol. What we have is plans for updating the data set of patients that have been previously enrolled and pulling those timelines forward a bit more. So we'll be looking to do that in the next couple of months. Next question.
spk11: Thank you. And our next question comes from the line of Jeff Meacham with Bank of America. Your line is open. Please go ahead.
spk04: Hey, guys. Thanks for taking our questions. This is Alec on for Jeff. So my first question is on 314. Do you have a sense from your physician interactions what an acceptable frequency of rescue VEGF injections would be with 314 for clinical adoption, particularly taking into account the three-month dosing for Bayview and six months for Lucentis PDS? I know it may be a bit premature considering 314 just started pitfall study or will early next year. but would you also be able to provide your thoughts on reimbursement discussions and how those are evolving for gene therapies and whether payers would also be looking at the rate of rescue injections to make reimbursement decisions? Thanks.
spk07: Sure. Steve, I'll let you swing back to maybe some of the physician interaction in terms of intervals of treatment. Alec, thanks for the question. I mean, we have, you know, we're moving into pivotal phase of development, and we have started to engage. you know, the entire system in discussions about the value and need around changes in standard of care for wet AMD and a lot of receptivity to, you know, not just extending, but eliminating the intervals, you know, that exist around treatment in terms of compliance and convenience. I think we continue to view that gene therapy has a unique profile, you know, that adds a tremendous amount of value and really emphasized at this moment in time where, you know, this overhang of pandemic, you know, is really affecting and influencing, you know, I think we're hearing from people both, you know, on the care side as well as on, you know, the provider and reimbursement side. What is happening to people right now if they're not able to come in and get their regular treatments and how much more effect is that going to have on outcomes and ultimately on costs and productivity and other things? So, You know, a lot of people paying attention right now and through that engagement, I think the profile that we've had for a while has been to get, you know, at least half of the injections, you know, worldwide eliminated. You know, we've talked about this as our target product profile, taking a look at what the market is today for, you know, VEGF injection rates. And, you know, it hasn't moved all that much with respect to changes in labeling. You know, I think when you look at the clinical data, when you look at the sort of chronicity of how things like, Lucentis and ILEA and BOVU and maybe what's to come or coming forward hasn't moved the needle all that much. We need to be doing more, and that's where we're focused on that unmet need. In terms of where that value lands ultimately, you know, I think it's for a one-time treatment or one that is seeing dramatic reduction, 50% or more, in the use of existing therapy or therapies that are emerging that are incremental. We view a huge opportunity there and have been very pleased with the conversations and the responsiveness that we've been able to engage so far at the stakeholder level there. Steve, maybe you can talk to clinically what the engagement's been like.
spk05: Yeah, it's been very interesting. You raised a good point, Ken, on the COVID impact and how that's really shined a light on the importance of durability and ultimately the possibility of a one-time treatment. And we're hearing that anecdotally. not only for the patients in our ongoing study who fortunately have been able to have the need for reinjection eliminated, where we've seen real-time patients in surge areas who've been able to miss a visit or two, which we don't like from a clinical trial standpoint, but from an overall benefit-risk, the ability to have the comfort that you have the foundational anti-VEGF treatment that you need, and you're not risking, you know, potentially vision-threatening complications by extending your visits. And it really comes back to how these physicians and their patients and their caregivers evaluate the benefit-risk. And you raised B of U and PDS, and As you know, retina's a dynamic space, and it's been a dynamic space. So we've known about these programs for a while, and that target product profile that Ken reviewed of at least 50% reduction, you know, either looking in terms of treatment burden or even looking in terms of patients who can completely have need for reinjections done away with, that hasn't changed in our minds because it hasn't changed in the minds of the investigators and our retina specialist advisors and their view of what's needed for their patients. And it's interesting, we don't really think of any of these welcomed advances in terms of these approved and other experimental agents that are able to advance to durability intervals of three to four months or five months or even six months as competition. If anything, these are clear validation of how much need there is to get more durable, sustainable treatments. And the ultimate way to do that would be a one-time injection. So we continue to see this as further validation for a one-time treatment and, you know, continue to see support for the target product profile that Ken elaborated on.
spk07: Yeah, and remember, you know, we feel that with the work we've already done in the assessment of subretinal at multiple dose levels, we have outperformed that target product profile and in a very challenged and severe population of patients. So, you know, we're feeling very good about the progress and the data set there as we're funneling it into a pivotal phase of development and also looking to differentiate the profile with suprachoroidal. So thanks, Alec, for the question.
spk11: Thank you. And our next question comes from the line of Bola Amusa with Chardon. Your line is open. Please go ahead.
spk02: Hi. Thanks for taking my call. I have two questions. The first is on manufacturing, given that you have internal coming online, which people recognize have certain advantages. But we've also heard that it's not just having a facility or a footprint. It's the processes, analytics. So could you talk about what you're doing to sort of have a best practice on those dimensions or anything you may be doing to avoid some of the growing pains that we've seen in the AV-based gene therapy space with regards to
spk07: Yeah, Bola, thanks a lot. I'm glad you went there because, you know, it's a – well, I think it previously has been a subtle but maybe, you know, less and less subtle point for investors on these areas. And I would say that even with our existing supply chain and the, you know, strong collaborations we have with, you know, bulk manufacturers and final fill finish with groups like Fuji and others, We have installed capabilities here in Rockville already in labs for analytics, quality assurance, quality control, assessment, release criteria that relate to not only the AAV side of the equation, but let's not forget about the device and route of administration side here. We're working with, you know, subretinal procedures. We're working with suprachoroidal procedures. We're working with intracisternal procedures and intravenous procedures. So, you know, we have compatibility with all of the devices that are being sent to these sites clinically and commercially as well. And that's been a major focus of quality, of sort of strong analytical capabilities, you know, assessing things across a wide range of different types of AAV vectors when it comes to things like potency as well has been really important to have that expertise internally. And that's already here. So, In some ways, what we're actually bringing further into Rockville, in our view, is more of the commodity scale things that we need to take the next steps in terms of insulating ourselves with respect to especially that commercial supply chain risk. But we think that we have a really strong foundation in a lot of those other areas that, as you pointed out, I think have been stumbling blocks and certainly can be, especially in a new and emerging area of science and manufacturing science. Next question.
spk11: Our next question comes from the line of Matthew Harrison with Morgan Stanley. Your line is open. Please go ahead.
spk08: Hello, everyone. This is for Matthew. I have a quick question on your CLM2 programs. Can you please talk about the status of the programs and what needs to be done before you file for the IND in 2021? Thank you.
spk07: Sure, Costas. Just at a high level, I'll see if Steve has anything else to add. We're guiding here to milestones that are very soon with respect to those two programs. In the case of both, we are really having completed the preclinical study evaluation phase and readout phase and keeping in mind that certain things like the 181 program in particular is borrowing also from existing IND and ongoing study packages from things like 121, for instance. You know, we're really translating that right now into written word and, you know, the modules of the IND filings. And similarly for RGX381, you know, we're using route of administration that we're familiar with. We've already highlighted that we've reported data from non-human primates demonstrating, you know, sustained levels of things like the enzyme TPP1, you know, in vitreous following a subretinal injection. So similarly, you know, we're in a phase right now here at the beginning of November where to be filing an IND by the end of the year. We're literally in the final phases of preparing the reports and writing the documents to be submitted. So I hope that helps. Thank you.
spk11: Our next question comes from the line of Manny Faruhar with SVB Lear Inc. Your line is open. Please go ahead.
spk03: Hey, good afternoon, everyone. This is Rick Eiling from Mani, and thanks for taking our questions. So now that the Pivotal 314 trial is set to start the first quarter of 2021, we're hoping to get some color on the trial design. Have you received any feedback from the FDA regarding the Pivotal endpoints, what the control arm would look like, duration of endpoints, or any other aspect of trial design?
spk07: Hey, Rick, thanks. No, not that we're updating today, and we will plan to update that at the beginning of next year when we talk about the initiation of the study. So, you know, we continue to, you know, guide to the fact that we think moving into pivotal phase of development in retina, you know, has some familiarity with the agency for different types of products, different types of modalities, things that I've already brought up on this call, of course, like recently BOVU and, of course, PDS and so forth. So, you know, we're not expecting people to be surprised here with some, you know, massive departure in certain ways with respect to how things are considered at FDA when it comes to wet AMD and retina. However, there's obviously a gene therapy bent to it and an RGX314 bent as well. And we definitely will come forward clearly with more details on that study design early next year. Steve, anything else to add at this stage?
spk05: No, you covered it nicely. We're excited to move into this stage. And yeah, we're about there.
spk11: Thank you. And again, ladies and gentlemen, if you have a question at this time, please press star then one. And our next question comes from the line of Lisa Walter with RBC Capital Markets. Your line is open. Please go ahead.
spk10: Hi there, this is Lisa Walter on the line for Lucaissi at RBC. Thanks for taking my question. We just wanted to ask if we could have an update on the IP dispute going on between you and Passage Bio as well as Sarepta. Thanks.
spk07: Hi, Lisa. Thanks a lot. We don't have any specific updates to provide today. We, you know, have provided information previously on, or I guess, you know, provided feedback with respect to our interest in making sure that people that are working with intellectual property and science that overlaps with our nav technology platform are under licensed so that they're free to do so, but also, you know, fairly representing what they're doing with respect to their science, and that we're looking out for the interest of, you know, we think not only our shareholders and stakeholders, but the interest of IP in general in our biotechnology space overall. And that also, it tends to be, you know, groups that we view that are getting closer to commercialization, you know, sort of come up higher, if you will, on our radar screen with respect to, you know, sort of action and interest that we have overall. So nothing more specific to update on today other than that's our philosophy. We think it's an important one to be not only – reflecting that we are and view IP as important as an industry and as a field in gene therapy, but also specifically for our shareholders. And hope to have more updates on those actions coming into 2021 and throughout the year. Thanks for the question.
spk11: Thank you. And we have a follow-up question from the line of Bola Amuso with Chardon. Your light is open. Please go ahead.
spk02: Hi, thanks again. And this one, first of all, congrats on the $80 million payment on Zulgensma. I get asked a lot about how long I should model the royalties from Novartis. So, you know, I've noticed that you do have patent term extension and supplementary protection certificates as a process ongoing in multiple jurisdictions given additional approvals. Would you say we analysts should think of those as relevant to the duration of the royalty payments, or are they less relevant? What can you say? What's the 101 on them?
spk07: Hey, Bola. Thanks. 101, I like that. AVXS 101, that was clever. The work that we're doing around patent term extension, I think it's, I mean, All of you on the cell side, I think, understand much about the processes on the biologic side in particular. We have approvals now that are occurring. It started in the U.S. and now has carried over into other jurisdictions in Europe and Japan. So the process of filing for patent term extension, keeping in mind that as we've always discuss, but just to reemphasize, you know, the NAV technology platform and the patents that underpin the compositions and the methods of use and so forth that fall under our licenses are worldwide, right? And they have issued claims in all the jurisdictions, so we follow through with the pursuit of patent term extension at sort of normal course in each one of those jurisdictions on an individual or case-by-case basis as they're approved. And similarly, you know, our license in this case with, Avexis, I guess Novartis Chain Therapies now, you know, as we amended and expanded it, it includes a license to a lot of patents in our portfolio relating to Zolgensma and AVXS 101. The norm is to, you know, file and get feedback and manage the process for potential to extend in many jurisdictions up to five years. You know, we've guided that with respect to how quickly Zolgensma got approved in the U.S., the likelihood of extending or the possibility of extension is actually curbed a bit. It's going to be closer to, I think, somewhere between three and four years. But we think it is entirely appropriate to be following that process, expecting that it occurs similar in nature to how biotechnology and biological products, existing products, have had patents extended to protect them and that three years in the U.S. or more and up to five years in jurisdictions like Europe and Japan are appropriate to consider based on how the license is structured, the type of IP that's being provided to protect Zolgensma and the value in it for us and Novartis gene therapies.
spk11: Thank you. And I'm showing no further questions at this time, and I would like to turn the conference back over to Mr. Ken Mills for any further remarks.
spk07: Okay. Thank you, operator. Thanks, everyone, for the questions. You know, most importantly, I hope everyone is safe, healthy, and well. It's been an interesting year, and we definitely will be in touch with everyone at between now and the end of the year with more updates and milestones as we've guided to, as well as, you know, some conferences that are coming up and really excited to transition from 2020, maybe with a new outlook in general, but positive nonetheless. We've accomplished a lot in 2020 coming into 2021. We look to continue to build on that. And again, appreciate all the questions. Appreciate the listening. Hope everyone's well and have a great evening.
spk11: Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program and you may all disconnect. Everyone, have a great day. Thank you. you Thank you. Thank you. Thank you. Thank you. you
Disclaimer